FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145873216> ?p ?o ?g. }

• W2145873216 abstract "Based on WHO Criteria-1997, osteoporosis (OST) can be diagnosed clinically when the BMD (by DEXA) of the spine, hip or mid-radius is over-2.5 standard deviation (SD) below that of the young adult. In clinical practice, the most frequent OSTS can be categorized into 3 types, Type I-OST (PMO Post Menopause OST), Type II-OST (ARO Age-Related OST), and Type III-OST (CIO Corticosteroid-Induced OST). Diabetic osteopenia and osteoporosis become major issues in daily clinical experiences. Recent studies indicated that the probable causes of diabetic osteopenia can be suggested 1 AGE-modified collagen affected osteoblastic cell differentiation and function; 2. could be responsible for osteopenia-osteoporosis (esp. in post-menopause) in patients with diabetes mellitus. One of the 3 Missions of International Osteoporosis Foundation is to motivate people to take action to prevent, diagnose, and treat Ost. The Treatment Update of OST can also be grouped into three interventions 1 Healthy Life Style as mentioned in the Prevention, 2 Calcium Supplement 1-1.5 g/day, 3A Drugs (Estrogen, Bisphosphonates, Calcitonin, Growth Hormone, SERMs, Strontium Ranelate (SR), Vitamin D, Fluoride, PTH-PTHRP, and 3B Symptomatic (Lumbar Support etc). The 3rd Generation (Gen.) Bisphosphonates (BISPs) investigated in humans, numbered in increasing order of potency are Neridronate, Aledronate, Olpadronate, Risedronate, Ibandronate, Zoledronate. Alendronate (ALE) and Risedronate (RIS) are available in Indonesia. The novel BISP, Risedronate (RIS) is 5-fold more potent than ALE. Most recent studies on PMO demonstrated that RIS of 35 mg, or 50 mg Once a Week (OaW) provided the same efficacy and safety as the daily 5 mg regimen; therefore, the lower dose, 35 mg OaW can be considered as optimal dose for PMOs or other osteoporotic patients who desire OaW regimen. In addition, RIS can be prescribed without dosage adjustment for patients with mild or moderate renal impairment (creatinine clearance more than 20 ml/minute). Conclusions OST, such as PMO, ARO, CIO, and diabetic osteopenia are the most prevalent bone disorders affecting ageing adults in Indonesia. Motivation of people to take action of prevention and treatment of OST should be intensified and socialized. RIS, a novel 3rd Gen-BISP has been proven to be effective and safe to prevent and to treat OST in a dosage of 5 mg OD, even with the same efficacy and safety if such a drug to be given 35 mg once a week. Importantly, it can be given safely without dosage adjustment as long as creatinine clearance of patients is more than 20 ml/min." @default.
• W2145873216 created "2016-06-24" @default.
• W2145873216 creator A5063812781 @default.
• W2145873216 date "2005-10-01" @default.
• W2145873216 modified "2023-09-24" @default.
• W2145873216 title "Review Article and Clinical Experience: Preventive and Therapeutic Strategies for Osteoporosis (A Highly Efficacious Risedronate-35 mg Once Weekly)" @default.
• W2145873216 cites W1826292625 @default.
• W2145873216 cites W1989637027 @default.
• W2145873216 cites W2022030212 @default.
• W2145873216 cites W2056810908 @default.
• W2145873216 cites W2071494980 @default.
• W2145873216 cites W2124527463 @default.
• W2145873216 cites W2125341063 @default.
• W2145873216 cites W2414682990 @default.
• W2145873216 hasPublicationYear "2005" @default.
• W2145873216 type Work @default.
• W2145873216 sameAs 2145873216 @default.
• W2145873216 citedByCount "0" @default.
• W2145873216 crossrefType "journal-article" @default.
• W2145873216 hasAuthorship W2145873216A5063812781 @default.
• W2145873216 hasConcept C124490489 @default.
• W2145873216 hasConcept C126322002 @default.
• W2145873216 hasConcept C134018914 @default.
• W2145873216 hasConcept C2776541429 @default.
• W2145873216 hasConcept C2776594446 @default.
• W2145873216 hasConcept C2776886416 @default.
• W2145873216 hasConcept C2777083390 @default.
• W2145873216 hasConcept C2777251235 @default.
• W2145873216 hasConcept C71924100 @default.
• W2145873216 hasConceptScore W2145873216C124490489 @default.
• W2145873216 hasConceptScore W2145873216C126322002 @default.
• W2145873216 hasConceptScore W2145873216C134018914 @default.
• W2145873216 hasConceptScore W2145873216C2776541429 @default.
• W2145873216 hasConceptScore W2145873216C2776594446 @default.
• W2145873216 hasConceptScore W2145873216C2776886416 @default.
• W2145873216 hasConceptScore W2145873216C2777083390 @default.
• W2145873216 hasConceptScore W2145873216C2777251235 @default.
• W2145873216 hasConceptScore W2145873216C71924100 @default.
• W2145873216 hasIssue "4" @default.
• W2145873216 hasLocation W21458732161 @default.
• W2145873216 hasOpenAccess W2145873216 @default.
• W2145873216 hasPrimaryLocation W21458732161 @default.
• W2145873216 hasRelatedWork W1020382261 @default.
• W2145873216 hasRelatedWork W1497094314 @default.
• W2145873216 hasRelatedWork W1990464463 @default.
• W2145873216 hasRelatedWork W2000619372 @default.
• W2145873216 hasRelatedWork W2010030427 @default.
• W2145873216 hasRelatedWork W2024045126 @default.
• W2145873216 hasRelatedWork W2025254960 @default.
• W2145873216 hasRelatedWork W2041135386 @default.
• W2145873216 hasRelatedWork W2043846572 @default.
• W2145873216 hasRelatedWork W2057461358 @default.
• W2145873216 hasRelatedWork W2111831005 @default.
• W2145873216 hasRelatedWork W2151812971 @default.
• W2145873216 hasRelatedWork W2324574911 @default.
• W2145873216 hasRelatedWork W2412392109 @default.
• W2145873216 hasRelatedWork W2436536720 @default.
• W2145873216 hasRelatedWork W2808597671 @default.
• W2145873216 hasRelatedWork W3025024932 @default.
• W2145873216 hasRelatedWork W3080312781 @default.
• W2145873216 hasRelatedWork W3126313451 @default.
• W2145873216 hasRelatedWork W58560150 @default.
• W2145873216 hasVolume "41" @default.
• W2145873216 isParatext "false" @default.
• W2145873216 isRetracted "false" @default.
• W2145873216 magId "2145873216" @default.
• W2145873216 workType "article" @default.